Stay updated with breaking news from Johnson rybrevant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology. ....
Yuhan, Elevar, Hengrui and Astellas—Fierce Pharma Asia fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
(Bloomberg) A new cancer medicine developed by AstraZeneca Plc and Daiichi Sankyo Co. seemed to fall short of investors’ expectations in partial results released early after a data leak at a medical conference. Most Read from BloombergBiden Vows Aid for Gaza, Backs Israel Over Hospital BlastHospital Blast Kills Hundreds as Israel, Hamas Trade BlameStocks Drop, Oil Climbs on Renewed Mideast Risks: Markets WrapUPenn Donors Pile Pressure on School as David Magerman Pulls SupportIsrael Latest: Bi ....
Takeda Pharmaceutical drug Exkivity failed the confirmatory study required of its 2021 accelerated approval. Our recap of other recent regulatory developments includes a partial clinical hold on a cancer drug, a Covid-19 vaccine authorization, and several drug approvals in the U.S. and beyond. ....